Pharmaceuticals

CF PHARMTECH

Changfeng Pharmaceutical spent HKD 529,700 to repurchase 24,000 shares

CangFeng Pharmaceutical 2025 Annual Report Shows Revenue Decline

Changfeng Pharmaceutical repurchased 18,500 shares for HKD 418,700

CF PHARMTECH released FY2025 earnings on March 30, 2026 (BJT) with actual revenue of HKD 472.73 M and EPS of HKD 0.0072

Changfeng Pharmaceutical Announces 2025 Annual Results, Highlighting Transformation and Development

Changfeng Pharmaceutical Signs Strategic Cooperation Agreement with JD Health in Respiratory and Nasal Field

CF PHARMTECH to Release FY2025 Earnings Report on March 30, 2026 (BJT)

Changfeng Pharmaceutical Issues Profit Warning for 2025 with Slumping Profits

Changfeng Pharmaceutical Announces Continuous Profitability and Future Financial Projections

Longfeng Pharmaceutical's Inhalation Powder Drug Candidate ICF001 New Drug Clinical Trial Application Approved

Changfeng Pharmaceutical's Self-developed Inhalation Powder Drug Clinical Trial Application Accepted by NMPA

Changfeng Pharmaceutical's Olodaterol Mometasone Nasal Spray Clinical Trial Application Approved by NMPA

Changfeng Pharmaceutical Holdings Repurchased 30,500 Shares for HKD 1.1801 Million

Longfeng Pharmaceutical's ICF004 Inhalation Powder Candidate Drug IND Application Accepted by NMPA

Changfeng Pharmaceuticals repurchased 8,000 shares

Changfeng Pharmaceutical Repurchased 16,500 Shares at a Cost of HKD 579,900

Changfeng Pharmaceutical repurchased 15,000 shares at a cost of approximately HKD 532,900

Changfeng Pharmaceutical's Inhaled Nucleic Acid Drug Development Project Selected for Jiangsu Science and Technology Major Special Program

Longfeng Pharmaceutical's Nasal Spray Clinical Trial Application Accepted by National Medical Products Administration

Changfeng Pharmaceutical Receives Acceptance for Clinical Trial Application of Fixed-Dose Combination Formulation

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02359

01528

06127

09959

01907

00326

01888

02652

01277

01898

WUXI APPTEC(02359) rose 13.57%, with a trading turnover 3.0 Billion HKD, and a year-to-date rose 45%. RS MACALLINE(01528) rose 11.11%, with a trading turnover 129.4 Million HKD, and a year-to-date rose 23%. JOINN(06127) rose 9.26%, with a trading turnover 216.2 Million HKD, and a year-to-date rose 14.6%.

Top Gainers&Losers

WUXI APPTEC

RS MACALLINE

JOINN

LINKLOGIS-W

CHINA RISUN GP

CHINA STAR ENT

KB LAMINATES

KINETIC DEV

CHINA COAL

Top 10 HK Stock Gainers (4.28)

CF PHARMTECH announced its full-year results for the year ended December last year, with a revenue of RMB 433 million, a year-on-year decrease of 28.8%. The net profit was RMB 2.485 million, a year-on-year decrease of 88.2%; earnings per share were 0.66 cents. No dividend was declared. Under non-International Financial Reporting Standards, the adjusted profit last year fell by 38.8% to RMB 31.751 million

AASTOCKS

"Performance" CF PHARMTECH's annual net profit is 2.485 million RMB, down 88.2%

CF PHARMTECH issued a profit warning, expecting that the profit for the fiscal year 2025 will drop to between RMB 2 million and RMB 3 million, a significant decrease from RMB 21.09 million in the previous year. The adjusted net profit is expected to be between RMB 30 million and RMB 35 million, with revenue ranging from RMB 410 million to RMB 450 million, down from RMB 608 million in the previous year. The main reasons include a decrease in product prices, reduced market demand, increased R&D expenses, and one-time listing expenses

"Profit Warning" CF PHARMTECH forecasts last year's profit to decrease to a maximum of 3 million RMB

CF PHARMTECH rose 17.47%; CSPC Pharmaceutical Group rose 1.65%, with a transaction volume of HKD 59.53 million; China Biologic Products Holdings rose 1.32%, with a transaction volume of HKD 32.41 million; Hansoh Pharmaceutical rose 0.79%, with a transaction volume of HKD 30.24 million; Heng Rui Medicine rose 0.61%, with a market value of HKD 437.4 billion

HK Stock Alerts

Hong Kong stock movement: CF PHARMTECH rises 17.47%, driven by dual benefits of new drug approval and capital inflow boosting stock price surge

02627

06869

01873

02546

00373

06166

03858

02670

AB&amp;B BIO-TECH-B(02627) fell 16.09%, with a trading turnover 43.7 Million HKD, and a year-to-date fell 4.1%. YOFC(06869) fell 12.39%, with a trading turnover 4.2 Billion HKD, and a year-to-date rose 170.8%. CF PHARMTECH(02652) fell 11.82%, with a trading turnover 63.2 Million HKD, and a year-to-date fell 29.7%.

AB&B BIO-TECH-B

YOFC

VIVA BIOTECH

ZHIHUI MINING

ALLIED GROUP

JIAXIN INTL RES

YUNJI

Top 10 HK Stock Losers (3.17)

CF PHARMTECH fell 10.96%; CSPC Pharmaceutical Group rose 0.78%, with a transaction volume of HKD 565 million; China Biologic Products Holdings had a transaction volume of HKD 243 million; Hansoh Pharmaceutical rose 1.54%, with a transaction volume of HKD 228 million; Heng Rui Medicine rose 1.62%, with a market value of HKD 437.4 billion

Hong Kong stock movement: CF PHARMTECH benefits from new drug application but falls nearly 11%. How do geopolitical issues and AI impacts affect market confidence?

02442

06683

03986

00376

00187

02513

06603

06088

02517

EASY SMART GP(02442) rose 68.97%, with a trading turnover 23.5 Million HKD, and a year-to-date rose 13.1%. STARPLUS LEGEND(06683) rose 25.82%, with a trading turnover 1.4 Billion HKD, and a year-to-date rose 73.6%. CF PHARMTECH(02652) rose 21.39%, with a trading turnover 256.1 Million HKD, and a year-to-date fell 20.2%.

EASY SMART GP

STARPLUS LEGEND

GIGADEVICE

YUNFENG FIN

JINGCHENG MAC

KNOWLEDGE ATLAS

IFBH

FIT HON TENG

GUOQUAN

Top 10 HK Stock Gainers (3.16)

CF PHARMTECH surged 24.70%; CSPC Pharmaceutical Group rose 1.98%, with a transaction volume of HKD 132 million; United Laboratories fell 2.98%, with a transaction volume of HKD 71.94 million; Hansoh Pharmaceutical dropped 0.67%, with a transaction volume of HKD 67.83 million; Heng Rui Medicine increased by 0.78%, with a market value of HKD 428.1 billion

Hong Kong Stock Movement: CF PHARMTECH surged 24.70%, as the approval of its new drug clinical application sparked market enthusiasm

CF PHARMTECH announced that its self-developed inhalation powder candidate drug ICF001 has been accepted for clinical trial application by the National Medical Products Administration of China. ICF001 is an innovative long-acting inhalation powder candidate drug developed based on a prodrug technology platform, specifically designed for the treatment of pulmonary arterial hypertension and related severe pulmonary diseases

CF PHARMTECH's candidate drug ICF00 clinical trial application has been accepted

02025

01384

02685

02637

00551

00020

02665

RUIFENG POWER(02025) fell 24.89%, with a trading turnover 17.3 Million HKD, and a year-to-date fell 0.6%. DEEPEXI TECH(01384) fell 15.6%, with a trading turnover 107.2 Million HKD, and a year-to-date rose 5.6%. CF PHARMTECH(02652) fell 13.72%, with a trading turnover 33.3 Million HKD, and a year-to-date fell 28.5%.

CF PHARMTECH(02652.HK)